Clinical Trial Update: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating orvepitant for major depressive disorder was terminated; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Orvepitant (Orvepitant)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Depressive Disorder, Major | Phase 2 | Status: TERMINATED | Results posted: 2017-09-12